|






NIMH
Site Map
Depression
Overview of
Depression
Depression Screening Test
Diagnosis and Treatment
Suicide and Depression
Getting Help
People and Depression
Depression and Other Illness
Info for Employers
Bipolar Disorder
Overview of
Bipolar
Bipolar Screening Test
Suicide and Bipolar
In Children and Adolescents
Bipolar and Other Illnesses
Medications and Mental Disorders
Overview
Antidepressant Medications
Antimanic Medications
In Women, Children, Elderly
Index of Psychiatric Medications
back to
depression community
send this page to a friend
|
|
 |
Early Recognition and Treatment Bipolar Disorder In Children
and Adolescents and Schizophrenia
Archival Record of NIMH
Research Workshop (Summary) May 10-11, 1999
Critical Questions for Discussion:
A. Focus on Bipolar Disorder:
How early can bipolar disorder be
diagnosed?
What is the predictive value of the early
manifestations of bipolar illness in children (before puberty) and in
adolescents?
What is the risk/benefit ratio of treating
children and adolescents with "prodromal" symptoms? Which treatments
should be considered? For how long?
What is the potential impact of early
treatment on course of illness?
Mood stabilizers, such as lithium,
carbamazepine, and valproate, have been shown to be effective in treating acute
episodes of bipolar disorder and in preventing relapse and recurrence of
episodes in adults. How and to which extent can this knowledge be extrapolated
to children and adolescents? Which are the critical studies that need to be
conducted in order to fully establish valid treatment guidelines for treating
and preventing manic-depressive illness in children and in adolescents?
What are the ethical implications of early
treatment vs. non-treatment? What are the ethical aspects of conducting
research in this area?
B. Focus on Schizophrenia:
How early can schizophrenia be diagnosed?
What is the predictive value of the early
manifestations of psychosis in children (before puberty) and in adolescents?
What is the risk/benefit ratio of treating
children and adolescents with early manifestations of psychosis
("prodromal" symptoms)? Which treatments should be considered? For
how long?
What is the potential impact of early
treatment on course of illness?
Atypical antipsychotics have a more
favorable profile of effects and side effects than classic neuroleptics, but
data in children are limited. What are the main safety concerns that must be
addressed in pediatric patients? Using which study designs?
What are the ethical implications of early
treatment vs. non-treatment? What are the ethical aspects of conducting
research in this area?
Main Conclusions
Bipolar
Disorder
It is recognized, based on retrospective
reports, that bipolar disorder often starts in the first two decades of life.
While the disorder can be usually recognized during adolescence, it is, in many
cases, difficult to formulate a definitive diagnosis in prepubertal years.
Controversy exists among experts on how to interpret extreme volatility of
mood, temper, and behavior in children. The presence of bipolar disorder in
other biologically related members of the family is an important element to be
considered in formulating a diagnosis of bipolar disorder in children.
A proper and prompt diagnosis of bipolar
disorder in children is important. If the disorder is not recognized, these
children may be exposed to treatments with stimulants or antidepressants that
may worsen the underlying mood disorder. On the other hand, an inaccurate
diagnosis of bipolar can lead to unnecessary exposure to mood stabilizers, such
as lithium and valproate, which can also cause side effects.
A systematic, prospective, and extended
evaluation of cohorts of children (including young children of preschool age)
who are characterized by extreme mood changes can provide information on the
clinical meaning of early mood lability and possible implications for later
development of bipolar disorder.
Little information is currently available
on the efficacy and safety of the commonly used mood stabilizers in youths with
bipolar disorder. Extrapolations of data from adult studies is in general not
appropriate, especially with respect to safety data. Children may be more prone
to certain side effects of medications than adults. Some data exist on the
safety of valproate, which is commonly used for seizure control also in
children. Still important unresolved questions remain about its possible role
in inducing polycystic ovary syndrome in adolescent girls. Controlled studies
are urgently needed in this area, with special emphasis on the long-term impact
of these treatments on symptoms, disorder prognosis, physical and cognitive
development.
Schizophrenia
The diagnosis of schizophrenia is seldom
made in prepubertal years. In part, this is due to the current uncertainty in
interpreting symptoms of abnormal cognitive and behavioral functioning at this
age. Systematic study and follow-up of multidimensionally impaired children may
help identify valid precursors and prodromic signs of schizophrenia.
A few studies on youths with prodromic
signs of psychosis are in progress. This research is extremely interesting and
promises to shed some light on the therapeutic value of very early treatment
interventions.
Important ethical issues must be addressed
in considering, planning and conducting early treatment research in the
prodrome of schizophrenia. A distinction must be clearly made between treatment
of existing symptoms that are accompanied by clinical dysfunction and
preventive interventions for subjects currently at risk but not clinically
impaired.
No adequate information exists on the
efficacy and safety of antipsychotic medications prescribed to youths with
schizophrenia and other psychotic disorders. This dearth is particularly
evident for the atypical antipsychotics. Extrapolations of data from adult
studies is in general not appropriate, especially with respect to safety data.
Children may be more prone to certain medication side effects than adults.
Controlled studies are urgently needed in this area, with special emphasis on
the long-term impact of these treatments on symptoms, disorder prognosis,
cognitive functions and development.
Updated: May 24, 2000
top | pages 1 2 3 4 |
site map |
send to
friend
overview
bipolar | screening test |
treatment | suicide | in
children
psychiatric medications | depression info
HealthyPlace.com
Depression Center Links
home ~ site map
|
 |
|
advertisement |